Therapy News and Research

RSS

Pegloticase can improve clinical outcomes of patients with chronic gout

Injections of pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in 2 out of 5 patients with chronic gout that is resistant to conventional therapies, researchers report in the August 17, 2011, issue of JAMA.

17 Aug 2011

Researchers identify five SNPs linked with aggressive, lethal prostate cancer

An international team of researchers led by Fred Hutchinson Cancer Research Center has identified five inherited genetic variants that are strongly associated with aggressive, lethal prostate cancer.

17 Aug 2011

Seattle Children's receives Gates Foundation grant to complete development of Sea-PAP

Seattle Children's Research Institute today announced the receipt of a two-year, $2.3 million grant from the Bill & Melinda Gates Foundation to complete prototype development of its new respiratory support device, called Seattle Children's Positive Airway Pressure.

17 Aug 2011

Drug SLM3 prevents multiplication of tumor cells

Tumors that do not respond to chemotherapy are the target of a cancer therapy that prevents the function of two enzymes in mouse tumor cells, according to Pennsylvania medical researchers.

17 Aug 2011

FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients

Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).

17 Aug 2011

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase I combination trial of CUDC-101.

17 Aug 2011

LYSOGENE launches the first gene therapy clinical trials in Sanfilippo disease

LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.

16 Aug 2011

IMRT produces high response rate in patients with extranodal lymphoma of head and neck: Research

Lymphoma is a cancer that affects organs of the immune system, including the lymph nodes. In a subtype of the disease called extranodal lymphoma, tumors arise in non-lymphoid organs, such as the tongue and tonsils.

16 Aug 2011

FDA clears Resonance Health's MRI-Q System for cardiac T2* iron assessment

Resonance Health Ltd, a medical device company specializing in imaging core laboratory services has received FDA clearance to market its MRI-Q System.

16 Aug 2011

DJOFL second quarter net sales increase 14.5% to $277.8 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the second quarter of fiscal 2011, ended July 2, 2011.

16 Aug 2011

Scientists define relationship between two prostate tumor suppressor genes

Of the 250,000 American men who will be diagnosed with prostate cancer this year, very few of them-about 1 percent-will develop lethal, metastatic disease. Finding a way to distinguish between this small cohort and the majority of patients who will develop an indolent, non-lethal form of prostate cancer is a key goal in prostate cancer research.

16 Aug 2011

Inflammation linked with RA increases patients risk of heart disease

Rheumatoid arthritis (RA) sufferers are at an increased risk of dying due to cardiovascular disease. A new five year study published in BioMed Central's open access journal Arthritis Research & Therapy showed that the risk of cardiovascular disease for people with RA is due to disease-related inflammation as well as the risk factors which affect the general population.

16 Aug 2011

New system could improve prostate cancer IMRT treatment plans

Prostate cancer, the most common form of cancer in U.S. men, is also one of the most treatable: 90 percent of patients who undergo intensity modulated radiation therapy (IMRT) in the early stages are disease free after five years, according to the journal Seminars in Radiation Oncology.

16 Aug 2011

Gene therapy cocktail can treat inherited diseases with 'misfolded' proteins

In a kind of molecular gymnastics, scientists at the University of North Carolina at Chapel Hill School of Medicine have devised a gene therapy cocktail that has the potential to treat some inherited diseases associated with "misfolded" proteins.

16 Aug 2011

AHRQ's new Spanish-language guide on heart medications

A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.

16 Aug 2011

Combination immunotherapy more effective for patients with Sezary Syndrome

A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, reports a new study by dermatologists from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

16 Aug 2011

New pathway for type 2 diabetes

Newly diagnosed type 2 diabetics tend to have one thing in common: obesity. Exactly how diet and obesity trigger diabetes has long been the subject of intense scientific research.

16 Aug 2011

AVI BioPharma, MDA to initiate exon-51 Phase 2 trial in Duchenne muscular dystrophy

More than a decade of targeted Muscular Dystrophy Association-funded research, made possible as a result of generous public support of the MDA Labor Day Telethon and thousands of grass-roots special events, has today culminated in MDA providing financial assistance for the start of the first Phase 2 placebo-controlled, multiple dose efficacy, safety, tolerability and pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, as a potential therapy for Duchenne muscular dystrophy.

16 Aug 2011

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been enrolled in its ESPRIT Phase III clinical trial of Epanova, in patients with hypertriglyceridemia (TG level greater than or equal to 200 and < 500 mg/dL) despite treatment with a statin.

16 Aug 2011

New role for harmonin protein in Usher syndrome

University of Iowa scientists have discovered a new role for a protein that is mutated in Usher syndrome, one of the most common forms of deaf-blindness in humans. The findings, which were published Aug. 8 in Nature Neuroscience, may help explain why this mutation causes the most severe form of the condition.

16 Aug 2011